Type 2 Diabetes Treatment

Our international team of scientists, under the leadership of our company, have developed a set of safe and effective drugs for the treatment of type 2 diabetes. The result of this work was the development of an original drug called “Neogliptin” (chemical synthesis), patented in China, India, Russia and we also developed prototypes of unique innovative drugs: “Genopepta” - based on non-viral gene therapy DNA vector, and “Glicobact” - in the form of recombinant lactobacillus.

​

The project includes three independent areas at different stages of development:

​

1. “Neogliptin” – a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, an original drug that is at the final stage of preclinical trials. At the moment preparations for the start of Phase I clinical trials are underway. The intended use of the drug is T2DM therapy. Previous preclinical trials in vitro and in vivo have confirmed the effectiveness and safety of Neogliptin, putting it on a par with competing drugs from the leading pharmaceutical companies. There are several variants of finished dosage forms developed, intellectual property and scientific inventions are protected by patents in the China, India and Russian Federation, patent application in the USA is in process of formalization.

2. “Genopepta” – a gene therapy drug based on a own non-viral DNA vector. The DNA vector carries a structural element encoding glucagon-like peptide-1 (GLP-1), which is involved in the control of blood sugar levels. The intended use of the drug is to treat T2DM and counteract obesity. At present, we have a newly developed bacterial producer, in vitro preclinical trials are underway, we are in the process of formalizing intellectual property and selecting patent protection zones, and are also working on the optimization of the drug production technology.

3. “Glicobact” – a medicinal product in the form of intestinal bacteria in an enteric soluble shell (recombinant lactobacillus based on native line of human lactobacillus) producing GLP-1. The intended use of the drug is T2DM therapy and anti-obesity medication. At present, we have a newly developed recombinant bacterial product, in vitro preclinical studies are underway, we are in the process of formalizing intellectual property and selecting patent protection zones, and are also working on the optimization of the drug production technology.

​

​

Project advantages:

​

• Competitive strength: The drugs in the portfolio of the project have been developed on the basis of different platforms, which will enable a more flexible response to market changes and cover a larger number of patients;

• Manufacturability: When initiating the project, we emphasized the criterion of high mass availability for the patient of each developed medicine, so it is assumed that the production of all the above-mentioned medicines will be low-cost (on an industrial scale), which, in addition to availability, also makes it possible to ensure high margins of the project;

• Global market: A high prevalence of type 2 diabetes mellitus opens prospects for successful project implementation worldwide.

​

This project may become a substantial tool for expanding the portfolio of innovative medicines and will place the partners in a leading position in the market of medicines for the treatment of diabetes mellitus.

​

​

Partnerships & Alliances:

​Drawing on our advantages, as well as many years of experience in developing innovative drugs, we assess the probability of successful tests and the launch of our project onto the market as very high.

​

• We are currently looking to build alliances & partnerships with potential investors to promote our clinical research and prepare for a potential launch onto market.

• If you are interested in this opportunity, please use our contact form here.